Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Plexxikon Initiates Dosing In Phase 1 Trial For PLX3397
Plexxikon has initiated dosing of cancer patients with PLX3397 in its phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic
Plexxikon has initiated dosing of cancer patients with PLX3397 in its phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic
Astellas Pharma (Astellas) and Boehringer Ingelheim Pharmaceuticals, a US subsidiary of Boehringer Ingelheim, have reached an agreement with Impax Laboratories (Impax) to settle their pending US litigation. The
Galapagos has achieved the first milestone in its antibacterials and antivirals alliance with GlaxoSmithKline (GSK). The company received a E500,000 cash payment from GSK. To date, Galapagos has
Diamyd Medical has reported that 90% of the total 320 children and adolescents with type 1 diabetes for the European phase III study with the diabetes vaccine –
Shire has published the findings from a head-to-head clinical study, in Clinical Nephrology. The study compared the efficacy of two non-calcium based phosphate binders, Fosrenol (lanthanum carbonate) and
DelSiTech has signed a collaboration agreement with Orion Corporation. The agreement enables Orion to apply DelSiTech drug delivery technology in combination with its drug molecules for different therapeutic
The European Commission (EC) has granted marketing authorisation to Baxter International for Celvapan H1N1 pandemic vaccine, using the company’s Vero cell technology. Reportedly, Baxter continues to deliver vaccine
Entest BioMedical (ENTB), a majority-owned subsidiary of Bio-Matrix Scientific, has applied for an exploratory/development phase II grant from the National Cancer Institute (NCI). The company said that the
Odyssey Thera (Odyssey) has reported that it will receive milestone payments from one of its investors, Pfizer, following the latter’s decision to progress drug candidates studied by Odyssey
Angelini has received a letter from the FDA stating that it has appropriately addressed all deficiencies cited by the FDA, following its inspection of the manufacturing facility in